Breast cancer chemoprevention: Old and new approaches

Journal of Biomedicine and Biotechnology

Volumn 2012, Issue , 2012, Pages

  Cazzaniga, Massimiliano ^a   Bonanni, Bernardo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CELECOXIB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EXEMESTANE; GEFITINIB; KI 67 ANTIGEN; LAPATINIB; LETROZOLE; RALOXIFENE; RETINOID DERIVATIVE; TAMOXIFEN; TRASTUZUMAB; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANTIGEN EXPRESSION; BREAST CANCER; CANCER PREVENTION; CHEMOPROPHYLAXIS; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG MECHANISM; DRUG TISSUE LEVEL; DRUG TOLERABILITY; ENDOMETRIUM CANCER; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; LUNG EMBOLISM; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN INDUCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; BREAST TUMOR; FEMALE; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOPREVENTION; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 84864941592     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2012/985620     Document Type: Review

References (142)

1. Smigal C., Jemal A., Ward E., Cokkinides V., Smith R., Howe H. L., Thun M., Trends in breast cancer by race and ethnicity: update 2006 Ca-A Cancer Journal for Clinicians 2006 56 3 168 183 (Pubitemid 43847927)
2. Youlden D. R., Cramb S. M., Dunn N. A. M., Muller J. M., Pyke C. M., Baade P. D., The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality Cancer Epidemiology 2012 36 3 237 248
3. Tirona M. T., Sehgal R., Ballester O., Prevention of breast cancer (Part I): epidemiology, risk factors, and risk assessment tools Cancer Investigation 2010 28 7 743 750
4. Sporn M. B., Approaches to prevention of epithelial cancer during the preneoplastic period Cancer Research 1976 36 7 2699 2702
5. O'Shaughnessy J. A., Kelloff G. J., Gordon G. B., Dannenberg A. J., Waun K. H., Fabian C. J., Sigman C. C., Bertagnolli M. M., Stratton S. P., Lam S., Nelson W. G., Meyskens F. L., Alberts D. S., Follen M., Rustgi A. K., Papadimitrakopoulou V., Scardino P. T., Gazdar A. F., Wattenberg L. W., Sporn M. B., Sakr W. A., Lippman S. M., Von Hoff D. D., Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development: recommendations of the American association for cancer research Task force on the Treatment and Prevention of intraepithelial neoplasia Clinical Cancer Research 2002 8 2 314 346 (Pubitemid 34193948)
6. Braakhuis B. J. M., Tabor M. P., Kummer J. A., Leemans C. R., Brakenhoff R. H., A genetic explanation of slaughter's concept of field cancerization: evidence and clinical implications Cancer Research 2003 63 8 1727 1730 (Pubitemid 36460827)
7. Althuis M. D., Fergenbaum J. H., Garcia-Closas M., Brinton L. A., Madigan M. P., Sherman M. E., Etiology of hormone receptor-defined breast cancer: a systematic review of the literature Cancer Epidemiology Biomarkers and Prevention 2004 13 10 1558 1568 (Pubitemid 39331875)
8. Pelekanou V., Leclercq G., Recent insights into the effect of natural and environmental estrogens on mammary development and carcinogenesis International Journal of Developmental Biology 2011 55 7-9 869 878
9. Shanle E. K., Xu W., Selectively targeting estrogen receptors for cancer treatment Advanced Drug Delivery Reviews 2010 62 13 1265 1276
10. Jordan V. C., Selective estrogen receptor modulation: a personal perspective Cancer Research 2001 61 15 5683 5687 (Pubitemid 32769076)
11. Early Breast Cancer Trialists Collaborative Groups, Tamoxifen for early breast cancer: an overview of the randomized trials The Lancet 1998 351 1451 1467
12. Fisher B., Costantino J. P., Wickerham D. L., Redmond C. K., Kavanah M., Cronin W. M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., Wolmark N., Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study Journal of the National Cancer Institute 1998 90 18 1371 1388 (Pubitemid 28439961)
13. King M. C., Wieand S., Hale K., Lee M., Walsh T., Owens K., Tait J., Ford L., Dunn B. K., Costantino J., Wickerham L., Wolmark N., Fisher B., Tamoxifen and breast cancer incidence among women with inherited mutations in brca1 and brca2 national surgical adjuvant breast and bowel project (nsabp-p1) breast cancer prevention trial Journal of the American Medical Association 2001 286 18 2251 2256 (Pubitemid 33063147)
14. Cuzick J., First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial The Lancet 2002 360 9336 817 824 (Pubitemid 35257944)
15. Cuzick J., Powles T., Veronesi U., Forbes J., Edwards R., Ashley S., Boyle P., Overview of the main outcomes in breast-cancer prevention trials The Lancet 2003 361 9354 296 300 (Pubitemid 36126189)
16. Decensi A., Bonanni B., Guerrieri-Gonzaga A., Gandini S., Robertson C., Johansson H., Travaglini R., Sandri M. T., Tessadrelli A., Farante G., Salinaro F., Bettega D., Barreca A., Boyle P., Costa A., Veronesi U., Biologic activity of tamoxifen at low doses in healthy women Journal of the National Cancer Institute 1998 90 19 1461 1467 (Pubitemid 28482010)
17. Johnston S. R. D., Haynes B. P., Sacks N. P. M., McKinna J. A., Griggs L. J., Jarman M., Baum M., Smith I. E., Dowsett M., Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer Breast Cancer Research and Treatment 1993 28 3 241 250 (Pubitemid 24057152)
18. Guerrieri-Gonzaga A., Baglietto L., Johansson H., Bonanni B., Robertson C., Sandri M. T., Canigiula L., Lampreda C., Diani S., Lien E. A., Decensi A., Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial Cancer Epidemiology Biomarkers and Prevention 2001 10 9 967 970 (Pubitemid 32844905)
19. Decensi A., Robertson C., Viale G., Pigatto F., Johansson H., Kisanga E. R., Veronesi P., Torrisi R., Cazzaniga M., Mora S., Sandri M. T., Pelosi G., Luini A., Goldhirsch A., Lien E. A., Veronesi U., A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers Journal of the National Cancer Institute 2003 95 11 779 790 (Pubitemid 36798424)
20. Barrett-Connor E., Mosca L., Collins P., Geiger M. J., Grady D., Kornitzer M., McNabb M. A., Wenger N. K., Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women New England Journal of Medicine 2006 355 2 125 137 (Pubitemid 44050394)
21. Martino S., Cauley J. A., Barrett-Connor E., Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene Journal of the National Cancer Institute 2004 96 1751 1761 (Pubitemid 39654569)
22. Sporn M. B., Dowsett S. A., Mershon J., Bryant H. U., Role of raloxifene in breast cancer prevention in postmenopausal women: clinical evidence and potential mechanisms of action Clinical Therapeutics 2004 26 6 830 840 (Pubitemid 38943032)
23. Cummings S. R., Eckert S., Krueger K. A., Grady D., Powles T. J., Cauley J. A., Norton L., Nickelsen T., Bjarnason N. H., Morrow M., Lippman M. E., Black D., Glusman J. E., Costa A., Jordan V. C., The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial Journal of the American Medical Association 1999 281 23 2189 2197 (Pubitemid 29275701)
24. Ettinger B., Black D. M., Mitlak B. H., Knickerbocker R. K., Nickelsen T., Genant H. K., Christiansen C., Delmas P. D., Zanchetta J. R., Stakkestad J., Gler C. C., Krueger K., Cohen F. J., Eckert S., Ensrud K. E., Avioli L. V., Lips P., Cummings S. R., Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial Journal of the American Medical Association 1999 282 7 637 645 (Pubitemid 29384151)
25. Cauley J. A., Norton L., Lippman M. E., Eckert S., Krueger K. A., Purdie D. W., Farrerons J., Karasik A., Mellstrom D., Ng K. W., Stepan J. J., Powles T. J., Morrow M., Costa A., Silfen S. L., Walls E. L., Schmitt H., Muchmore D. B., Jordan V. C., Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial Breast Cancer Research and Treatment 2001 65 2 125 134 (Pubitemid 32193616)
26. Vogel V. G., Costantino J. P., Wickerham D. L., Cronin W. M., Cecchini R. S., Atkins J. N., Bevers T. B., Fehrenbacher L., Pajon Jr. E. R., Wade III J. L., Robidoux A., Margolese R. G., James J., Lippman S. M., Runowicz C. D., Ganz P. A., Reis S. E., McCaskill-Stevens W., Ford L. G., Jordan V. C., Wolmark N., Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial Journal of the American Medical Association 2006 295 23 2727 2741
27. Mosca L., Barrett-Connor E., Wenger N. K., Collins P., Grady D., Kornitzer M., Moscarelli E., Paul S., Wright T. J., Helterbrand J. D., Anderson P. W., Design and methods of the Raloxifene Use for The Heart (RUTH) study American Journal of Cardiology 2001 88 4 392 395 (Pubitemid 32823301)
28. Coates A. S., Keshaviah A., Thrlimann B., Mouridsen H., Mauriac L., Forbes J. F., Paridaens R., Castiglione-Gertsch M., Gelber R. D., Colleoni M., Lng I., Del Mastro L., Smith I., Chirgwin J., Nogaret J. M., Pienkowski T., Wardley A., Jakobsen E. H., Price K. N., Goldhirsch A., Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 Journal of Clinical Oncology 2007 25 5 486 492 (Pubitemid 350002953)
29. Coombes R., Kilburn L., Snowdon C., Paridaens R., Coleman R., Jones S., Jassem J., Van de Velde C., Delozier T., Alvarez I., Del Mastro L., Ortmann O., Diedrich K., Coates A., Bajetta E., Holmberg S., Dodwell D., Mickiewicz E., Andersen J., Lnning P., Cocconi G., Forbes J., Castiglione M., Stuart N., Stewart A., Fallowfield L., Bertelli G., Hall E., Bogle R., Carpentieri M., Colajori E., Subar M., Ireland E., Bliss J., Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial The Lancet 2007 369 9561 559 570
30. Goss P. E., Ingle J. N., Martino S., Robert N. J., Muss H. B., Piccart M. J., Castiglione M., Tu D., Shepherd L. E., Pritchard K. I., Livingston R. B., Davidson N. E., Norton L., Perez E. A., Abrams J. S., Therasse P., Palmer M. J., Pater J. L., A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer New England Journal of Medicine 2003 349 19 1793 1802 (Pubitemid 37362955)
31. Baum M., Buzdar A. U., Cuzick J., Forbes J., Houghton J., Klijn J. G. M., Sahmoud T., Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial The Lancet 2002 359 9324 2131 2139 (Pubitemid 34694019)
32. Howell A., Cuzick J., Baum M., Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer The Lancet 2005 365 9453 60 62
33. Coombes R. C., Hall E., Gibson L. J., Paridaens R., Jassem J., Delozier T., Jones S. E., Alvarez I., A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer New England Journal of Medicine 2004 350 11 1081 1092 (Pubitemid 38298988)
34. Perez E. A., Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer Annals of Oncology 2007 18 supplement 8 viii26 viii35
35. Cuzick J., Aromatase inhibitors for breast cancer prevention Journal of Clinical Oncology 2005 23 8 1636 1643 (Pubitemid 46211418)
36. Goss P. E., Strasser-Weippl K., Brown M., Santen R., Ingle J., Bissell M., Prevention strategies with aromatase inhibitors Clinical Cancer Research 2004 10 1 372S 379S (Pubitemid 38116645)
37. Cuzick J., IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole Expert Review of Anticancer Therapy 2008 8 9 1377 1385
38. Carey L. A., Perou C. M., Livasy C. A., Dressler L. G., Cowan D., Conway K., Karaca G., Troester M. A., Chiu K. T., Edmiston S., Deming S. L., Geradts J., Cheang M. C. U., Nielsen T. O., Moorman P. G., Earp H. S., Millikan R. C., Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study Journal of the American Medical Association 2006 295 21 2492 2502 (Pubitemid 43854964)
39. Moon R. C., Thompson H. J., Becci P. J., N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat Cancer Research 1979 39 4 1339 1346 (Pubitemid 9183854)
40. Budd G. T., Adamson P. C., Gupta M., Homayoun P., Sandstrom S. K., Murphy R. F., McLain D., Tuason L., Peereboom D., Bukowski R. M., Ganapathi R., Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer Clinical Cancer Research 1998 4 3 635 642 (Pubitemid 28193562)
41. Decensi A., Bonanni B., Baglietto L., Guerrieri-Gonzaga A., Ramazzotto F., Johansson H., Robertson C., Marinucci I., Mariette F., Sandri M. T., Daldoss C., Bianco V., Buttarelli M., Cazzaniga M., Franchi D., Cassano E., Omodei U., A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers Clinical Cancer Research 2004 10 13 4389 4397 (Pubitemid 38878879)
42. Cazzaniga M., Varricchio C., Montefrancesco C., Feroce I., Guerrieri-Gonzaga A., Fenretinide (4-HPR): A preventive chance for women at genetic and familial risk? Journal of Biomedicine and Biotechnology 2012 2012 9
43. Veronesi U., De Palo G., Marubini E., Costa A., Formelli F., Mariani L., Decensi A., Camerini T., Del Turco M. R., Di Mauro M. G., Muraca M. G., Del Vecchio M., Pinto C., D'Aiuto G., Boni C., Campa T., Magni A., Miceli R., Perloff M., Malone W. F., Sporn M. B., Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer Journal of the National Cancer Institute 1999 91 21 1847 1856
44. Veronesi U., Mariani L., Decensi A., Formelli F., Camerini T., Miceli R., Di Mauro M. G., Costa A., Marubini E., Sporn M. B., De Palo G., Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer Annals of Oncology 2006 17 7 1065 1071 (Pubitemid 43985241)
45. Wu K., Kim H. T., Rodriquez J. L., Hilsenbeck S. G., Mohsin S. K., Xu X. C., Lamph W. W., Kuhn J. G., Green J. E., Brown P. H., Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069 Cancer Epidemiology Biomarkers and Prevention 2002 11 5 467 474 (Pubitemid 34517942)
46. Wu K., Zhang Y., Xu X. C., Hill J., Celestino J., Kim H. T., Mohsin S. K., Hilsenbeck S. G., Lamph W. W., Bissonette R., Brown P. H., The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice Cancer Research 2002 62 22 6376 6380 (Pubitemid 35364089)
47. Lu C., Speers C., Zhang Y., Xu X., Hill J., Steinbis E., Celestino J., Shen Q., Kim H., Hilsenbeck S., Mohsin S. K., Wakeling A., Osborne C. K., Brown P. W., Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors Journal of the National Cancer Institute 2003 95 24 1825 1833 (Pubitemid 38054683)
48. Imai K., Takaoka A., Comparing antibody and small-molecule therapies for cancer Nature Reviews Cancer 2006 6 9 714 727 (Pubitemid 44286003)
49. Seshadri R., Firgaira F. A., Horsfall D. J., McCaul K., Setlur V., Kitchen P., Clinical significance of HER-2/neu oncogene amplification in primary breast cancer Journal of Clinical Oncology 1993 11 10 1936 1942 (Pubitemid 23304619)
50. Tandon A. K., Clark G. M., Chamness G. C., Ullrich A., McGuire W. L., HER-2/neu oncogene protein and prognosis in breast cancer Journal of Clinical Oncology 1989 7 8 1120 1128 (Pubitemid 19196537)
51. Konecny G., Pauletti G., Pegram M., Untch M., Dandekar S., Aguilar Z., Wilson C., Rong H. M., Bauerfeind I., Felber M., Wang H. J., Beryt M., Seshadri R., Hepp H., Slamon D. J., Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer Journal of the National Cancer Institute 2003 95 2 142 153 (Pubitemid 36193263)
52. Slamon D. J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L., Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2 New England Journal of Medicine 2001 344 11 783 792 (Pubitemid 32222155)
53. Brufsky A., Lembersky B., Schiffman K., Lieberman G., Paton V. E., Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer Clinical Breast Cancer 2005 6 3 247 252 (Pubitemid 47050801)
54. Buzdar A. U., Valero V., Ibrahim N. K., Francis D., Broglio K. R., Theriault R. L., Pusztai L., Green M. C., Singletary S. E., Hunt K. K., Sahin A. A., Esteva F., Symmans W. F., Ewer M. S., Buchholz T. A., Hortobagyi G. N., Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen Clinical Cancer Research 2007 13 1 228 233 (Pubitemid 46121873)
55. Gianni L., Eiermann W., Semiglazov V., Manikhas A., Lluch A., Tjulandin S., Zambetti M., Vazquez F., Byakhow M., Lichinitser M., Climent M. A., Ciruelos E., Ojeda B., Mansutti M., Bozhok A., Baronio R., Feyereislova A., Barton C., Valagussa P., Baselga J., Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort The Lancet 2010 375 9712 377 384
56. Baselga J., Perez E. A., Pienkowski T., Bell R., Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer Oncologist 2006 11 1 4 12
57. Hartmann J. T., Haap M., Kopp H. G., Lipp H. P., Tyrosine kinase inhibitorsa review on pharmacology, metabolism and side effects Current Drug Metabolism 2009 10 5 470 481
58. Cameron D., Casey M., Press M., Lindquist D., Pienkowski T., Romieu C. G., Chan S., Jagiello-Gruszfeld A., Kaufman B., Crown J., Chan A., Campone M., Viens P., Davidson N., Gorbounova V., Raats J. I., Skarlos D., Newstat B., Roychowdhury D., Paoletti P., Oliva C., Rubin S., Stein S., Geyer C. E., A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses Breast Cancer Research and Treatment 2008 112 3 533 543
59. Lin N. U., Carey L. A., Liu M. C., Younger J., Come S. E., Ewend M., Harris G. J., Bullitt E., Van Den Abbeele A. D., Henson J. W., Li X., Gelman R., Burstein H. J., Kasparian E., Kirsch D. G., Crawford A., Hochberg F., Winer E. P., Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer Journal of Clinical Oncology 2008 26 12 1993 1999
60. Di Leo A., Gomez H. L., Aziz Z., Zvirbule Z., Bines J., Arbushites M. C., Guerrera S. F., Koehler M., Oliva C., Stein S. H., Williams L. S., Dering J., Finn R. S., Press M. F., Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer Journal of Clinical Oncology 2008 26 34 5544 5552
61. Strecker T. E., Shen Q., Zhang Y., Hill J. L., Li Y., Wang C., Kim H. T., Gilmer T. M., Sexton K. R., Hilsenbeck S. G., Osborne C. K., Brown P. H., Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice Journal of the National Cancer Institute 2009 101 2 107 113
62. Harari P. M., Epidermal growth factor receptor inhibition strategies in oncology Endocrine-Related Cancer 2004 11 4 689 708 (Pubitemid 40065545)
63. Ciardiello F., Tortora G., A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor Clinical Cancer Research 2001 7 10 2958 2970 (Pubitemid 32963812)
64. Agrawal A., Gutteridge E., Gee J. M. W., Nicholson R. I., Robertson J. F. R., Overview of tyrosine kinase inhibitors in clinical breast cancer Endocrine-Related Cancer 2005 12 1 S135 S144
65. Dickler M. N., Rugo H. S., Eberle C., Brogi E., Caravelli J., Panageas K. S., Boyd J., Yeh B., Lake D. E., Dang C., Gilewski T. A., Bromberg J. F., Seidman A. D., D'Andrea G. M., Moasser M. M., Melisko M., Park J. W., Dancey J., Norton L., Hudis C. A., A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer Clinical Cancer Research 2008 14 23 7878 7883
66. Chan K. C., Knox W. F., Gee J. M., Morris J., Nicholson R. I., Potten C. S., Bundred N. J., Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast Cancer Research 2002 62 1 122 128 (Pubitemid 34073995)
67. Half E., Tang X. M., Gwyn K., Sahin A., Wathen K., Sinicrope F. A., Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ Cancer Research 2002 62 6 1676 1681 (Pubitemid 34408488)
68. Thun M. J., Jane Henley S., Patrono C., Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues Journal of the National Cancer Institute 2002 94 4 252 266 (Pubitemid 34196319)
69. Cuzick J., Otto F., Baron J. A., Brown P. H., Burn J., Greenwald P., Jankowski J., La Vecchia C., Meyskens F., Senn H. J., Thun M., Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement The Lancet Oncology 2009 10 5 501 507
70. Schottenfeld D., Beebe-Dimmer J., Chronic inflammation: a common and important factor in the pathogenesis of neoplasia Ca-A Cancer Journal for Clinicians 2006 56 2 69 83
71. Shim V., Gauthier M. L., Sudilovsky D., Mantei K., Chew K. L., Moore D. H., Cha I., Tlsty T. D., Esserman L. J., Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium Cancer Research 2003 63 10 2347 2350 (Pubitemid 36605165)
72. Khuder S. A., Mutgi A. B., Breast cancer and NSAID use: a meta-analysis British Journal of Cancer 2001 84 9 1188 1192 (Pubitemid 32511336)
73. Takkouche B., Regueira-Méndez C., Etminan M., Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis Journal of the National Cancer Institute 2008 100 20 1439 1447
74. Harris R. E., Alshafie G. A., Abou-Issa H., Seibert K., Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor Cancer Research 2000 60 8 2101 2103 (Pubitemid 30225166)
75. Nakatsugi S., Ohta T., Kawamori T., Mutoh M., Tanigawa T., Watanabe K., Sugie S., Sugimura T., Wakabayashi K., Chemoprevention by nimesulide, a selective cyclooxygenase-2 inhibitor, of 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP)-induced mammary gland carcinogenesis in rats Japanese Journal of Cancer Research 2000 91 9 886 892
76. Russell R. G. G., Bisphosphonates: the first 40 years Bone 2011 49 1 2 19
77. Rodan G. A., Fleisch H. A., Bisphosphonates: mechanisms of action Journal of Clinical Investigation 1996 97 12 2692 2696 (Pubitemid 26197084)
78. Brufsky A., Harker W. G., Beck J. T., Carroll R., Tan-Chiu E., Seidler C., Hohneker J., Lacerna L., Petrone S., Perez E. A., Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer Journal of Clinical Oncology 2007 25 7 829 836 (Pubitemid 350002883)
79. Hall T. J., Schaueblin M., A pharmacological assessment of the mammalian osteoclast vacuolar H + -ATPase Bone and Mineral 1994 27 2 159 166
80. Rennert G., Pinchev M., Rennert H. S., Use of bisphosphonates and risk of postmenopausal breast cancer Journal of Clinical Oncology 2010 28 22 3577 3581
81. Chlebowski R. T., Chen Z., Cauley J. A., Anderson G., Rodabough R. J., McTiernan A., Lane D. S., Manson J. E., Snetselaar L., Yasmeen S., O'Sullivan M. J., Safford M., Hendrix S. L., Wallace R. B., Oral bisphosphonate use and breast cancer incidence in postmenopausal women Journal of Clinical Oncology 2010 28 22 3582 3590
82. Amé J. C., Spenlehauer C., De Murcia G., The PARP superfamily BioEssays 2004 26 8 882 893 (Pubitemid 39128102)
83. Dantzer F., Amé J. C., Schreiber V., Nakamura J., Ménissier-de Murcia J., de Murcia G., Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair Methods in Enzymology 2006 409 493 510
84. Amé J. C., Rolli V., Schreiber V., Niedergang C., Apiou F., Decker P., Muller S., Hger T., Ménissier-de Murcia J., De Murcia G., PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase Journal of Biological Chemistry 1999 274 25 17860 17868
85. Peralta-Leal A., Rodrguez-Vargas J. M., Aguilar-Quesada R., Rodrguez M. I., Linares J. L., de Almodvar M. R., Oliver F. J., PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases Free Radical Biology and Medicine 2009 47 1 13 26
86. Calvert H., Azzariti A., The clinical development of inhibitors of poly(ADP-ribose) polymerase Annals of Oncology 2011 22 1 i53 i59
87. Rehman F. L., Lord C. J., Ashworth A., Synthetic lethal approaches to breast cancer therapy Nature Reviews Clinical Oncology 2010 7 12 718 724
88. Iglehart J. D., Silver D. P., Synthetic lethalitya new direction in cancer-drug development New England Journal of Medicine 2009 361 2 189 191
89. Evers B., Drost R., Schut E., De Bruin M., Van Burg E. D., Derksen P. W. B., Holstege H., Liu X., Van Drunen E., Beverloo H. B., Smith G. C. M., Martin N. M. B., Lau A., O'Connor M. J., Jonkers J., Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin Clinical Cancer Research 2008 14 12 3916 3925
90. Bryant H. E., Schultz N., Thomas H. D., Parker K. M., Flower D., Lopez E., Kyle S., Meuth M., Curtin N. J., Helleday T., Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 2005 434 7035 913 917 (Pubitemid 40559005)
91. O'Shaughnessy J., Osborne C., Pippen J. E., Yoffe M., Patt D., Rocha C., Koo I. C., Sherman B. M., Bradley C., Iniparib plus chemotherapy in metastatic triple-negative breast cancer New England Journal of Medicine 2011 364 3 205 214
92. Fong P. C., Boss D. S., Yap T. A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M. J., Ashworth A., Carmichael J., Kaye S. B., Schellens J. H. M., De Bono J. S., Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers New England Journal of Medicine 2009 361 2 123 134
93. Xue F., Michels K. B., Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. The American Journal of Clinical Nutrition 2007 86 3 s823 835
94. Hsu I. R., Kim S. P., Kabir M., Bergman R. N., Metabolic syndrome, hyperinsulinemia, and cancer. The American Journal of Clinical Nutrition 2007 86 3 s867 871
95. Goodwin P. J., Ennis M., Pritchard K. I., Trudeau M. E., Koo J., Madarnas Y., Hartwick W., Hoffman B., Hood N., Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study Journal of Clinical Oncology 2002 20 1 42 51 (Pubitemid 34032594)
96. Pasanisi P., Berrino F., De Petris M., Venturelli E., Mastroianni A., Panico S., Metabolic syndrome as a prognostic factor for breast cancer recurrences International Journal of Cancer 2006 119 1 236 238
97. Irwin M. L., McTiernan A., Bernstein L., Gilliland F. D., Baumgartner R., Baumgartner K., Ballard-Barbash R., Relationship of obesity and physical activity with C-peptide, leptin, and insulin-like growth factors in breast cancer survivors Cancer Epidemiology Biomarkers and Prevention 2005 14 12 2881 2888 (Pubitemid 43068820)
98. Gunter M. J., Hoover D. R., Yu H., Wassertheil-Smoller S., Rohan T. E., Manson J. E., Li J., Ho G. Y. F., Xue X., Anderson G. L., Kaplan R. C., Harris T. G., Howard B. V., Wylie-Rosett J., Burk R. D., Strickler H. D., Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women Journal of the National Cancer Institute 2009 101 1 48 60
99. Pollak M. N., Schernhammer E. S., Hankinson S. E., Insulin-like growth factors and neoplasia Nature Reviews Cancer 2004 4 7 505 518 (Pubitemid 38868620)
100. Belfiore A., Frasca F., Pandini G., Sciacca L., Vigneri R., Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease Endocrine Reviews 2009 30 6 586 623
101. Wolf I., Sadetzki S., Catane R., Karasik A., Kaufman B., Diabetes mellitus and breast cancer The Lancet Oncology 2005 6 2 103 111 (Pubitemid 40197704)
102. Pollak M., Insulin and insulin-like growth factor signalling in neoplasia Nature Reviews Cancer 2008 8 12 915 928
103. Evans J. M. M., Donnelly L. A., Emslie-Smith A. M., Alessi D. R., Morris A. D., Metformin and reduced risk of cancer in diabetic patients British Medical Journal 2005 330 7503 1304 1305 (Pubitemid 40813563)
104. Bowker S. L., Majumdar S. R., Veugelers P., Johnson J. A., Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin Diabetes Care 2006 29 2 254 258 (Pubitemid 44106500)
105. DeCensi A., Puntoni M., Goodwin P., Cazzaniga M., Gennari A., Bonanni B., Gandini S., Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis Cancer Prevention Research 2010 3 11 1451 1461
106. Sahra I. B., Laurent K., Loubat A., Giorgetti-Peraldi S., Colosetti P., Auberger P., Tanti J. F., Le Marchand-Brustel Y., Bost F., The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level Oncogene 2008 27 25 3576 3586 (Pubitemid 351793803)
107. Zakikhani M., Dowling R., Fantus I. G., Sonenberg N., Pollak M., Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells Cancer Research 2006 66 21 10269 10273 (Pubitemid 44799743)
108. Phoenix K. N., Vumbaca F., Claffey K. P., Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ER negative MDA-MB-435 breast cancer model Breast Cancer Research and Treatment 2009 113 1 101 111
109. Cazzaniga M., Bonanni B., Guerrieri-Gonzaga A., Decensi A., Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiology Biomarkers and Prevention 2009 18 3 701 705
110. Chen F., Castranova V., Shi X., New insights into the role of nuclear factor- B in cell growth regulation American Journal of Pathology 2001 159 2 387 397 (Pubitemid 32751067)
111. Lenardo M. J., Baltimore D., NK- B: a pleiotropic mediator of inducible and tissue-specific gene control Cell 1989 58 2 227 229 (Pubitemid 19191405)
112. Karin M., Nuclear factor- B in cancer development and progression Nature 2006 441 7092 431 436 (Pubitemid 44050137)
113. Karin M., NF- B and cancer: mechanisms and targets Molecular Carcinogenesis 2006 45 6 355 361
114. Bowie A., O'Neill L. A. J., Oxidative stress and nuclear factor- B activation: a reassessment of the evidence in the light of recent discoveries Biochemical Pharmacology 2000 59 1 13 23
115. Toledano M. B., Leonard W. J., Modulation of transcription factor NF- B binding activity by oxidation-reduction in vitro Proceedings of the National Academy of Sciences of the United States of America 1991 88 10 4328 4332 (Pubitemid 21914533)
116. Pahl H. L., Activators and target genes of Rel/NF- B transcription factors Oncogene 1999 18 49 6853 6866
117. Ahmad N., Gupta S., Mukhtar H., Green tea polyphenol epigallocatechin-3- gallate differentially modulates nuclear factor B in cancer cells versus normal cells Archives of Biochemistry and Biophysics 2000 376 2 338 346 (Pubitemid 30210882)
118. Bharti A. C., Donato N., Singh S., Aggarwal B. B., Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor- B and I B kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis Blood 2003 101 3 1053 1062 (Pubitemid 36139379)
119. Chinni S. R., Li Y., Upadhyay S., Koppolu P. K., Sarkar F. H., Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells Oncogene 2001 20 23 2927 2936 (Pubitemid 33027760)
120. Li Y., Sarkar F. H., Inhibition of nuclear factor B activation in PC3 cells by genistein is mediated via Akt signaling pathway Clinical Cancer Research 2002 8 7 2369 2377 (Pubitemid 34753612)
121. Li Y., Chinni S. R., Sarkar F. H., Selective growth regulatory and pro-apoptotic effects of DIM is mediated by Akt and NF-kappaB pathways in prostate cancer cells Frontiers in Bioscience 2005 10 1 236 243 (Pubitemid 40543031)
122. Brahimi-Horn M. C., Pouysségur J., The hypoxia-inducible factor and tumor progression along the angiogenic pathway International Review of Cytology 2004 242 157 213 (Pubitemid 39642963)
123. Esteban M. A., Maxwell P. H., HIF, a missing link between metabolism and cancer Nature Medicine 2005 11 10 1047 1048 (Pubitemid 41486820)
124. Semenza G. L., Targeting HIF-1 for cancer therapy Nature Reviews Cancer 2003 3 10 721 732 (Pubitemid 37328811)
125. Harris A. L., Hypoxiaa key regulatory factor in tumour growth Nature Reviews Cancer 2002 2 1 38 47 (Pubitemid 37328806)
126. Lpez-Lzaro M., HIF-1: hypoxia-inducible factor or dysoxia-inducible factor? FASEB Journal 2006 20 7 828 832
127. Semenza G. L., Development of novel therapeutic strategies that target HIF-1 Expert Opinion on Therapeutic Targets 2006 10 2 267 280
128. Giaccia A., Siim B. G., Johnson R. S., HIF-1 as a target for drug development Nature Reviews Drug Discovery 2003 2 10 803 811 (Pubitemid 37361812)
129. Nagle D. G., Zhou Y. D., Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1) Current Drug Targets 2006 7 3 355 369 (Pubitemid 43744851)
130. Yeo E. J., Chun Y. S., Park J. W., New anticancer strategies targeting HIF-1 Biochemical Pharmacology 2004 68 6 1061 1069
131. Zhong H., De Marzo A. M., Laughner E., Lim M., Hilton D. A., Zagzag D., Buechler P., Isaacs W. B., Semenza G. L., Simons J. W., Overexpression of hypoxia-inducible factor 1 in common human cancers and their metastases Cancer Research 1999 59 22 5830 5835
132. Schofield C. J., Ratcliffe P. J., Oxygen sensing by HIF hydroxylases Nature Reviews Molecular Cell Biology 2004 5 5 343 354 (Pubitemid 38579472)
133. Shou J., Massarweh S., Osborne C. K., Wakeling A. E., Ali S., Weiss H., Schiff R., Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer Journal of the National Cancer Institute 2004 96 12 926 935 (Pubitemid 38868139)
134. Mondesire W. H., Jian W., Zhang H., Ensor J., Hung M. C., Mills G. B., Meric-Bernstam F., Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells Clinical Cancer Research 2004 10 20 7031 7042 (Pubitemid 39383055)
135. Knuefermann C., Lu Y., Liu B., Jin W., Liang K., Wu L., Schmidt M., Mills G. B., Mendelsohn J., Fan Z., HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells Oncogene 2003 22 21 3205 3212 (Pubitemid 36712932)
136. Nahta R., Esteva F. J., HER2 therapy: molecular mechanisms of trastuzumab resistance Breast Cancer Research 2006 8 6, article 215
137. Junttila T. T., Akita R. W., Parsons K., Fields C., Lewis Phillips G. D., Friedman L. S., Sampath D., Sliwkowski M. X., Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 Cancer Cell 2009 15 5 429 440
138. Raymond E., Alexandre J., Faivre S., Vera K., Materman E., Boni J., Leister C., Korth-Bradley J., Hanauske A., Armand J. P., Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer Journal of Clinical Oncology 2004 22 12 2336 2347 (Pubitemid 41115390)
139. Yu K., Toral-Barza L., Discafani C., Zhang W. G., Skotnicki J., Frost P., Gibbons J. J., mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer Endocrine-Related Cancer 2001 8 3 249 258 (Pubitemid 32947647)
140. Li H., Lin J., Wang X., Yao G., Wang L., Zheng H., Yang C., Jia C., Liu A., Bai X., Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. Breast Cancer Research and Treatment. In press
141. Liu M., Howes A., Lesperance J., Stallcup W. B., Hauser C. A., Kadoya K., Oshima R. G., Abraham R. T., Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer Cancer Research 2005 65 12 5325 5336 (Pubitemid 40827345)
142. Namba R., Young L. J. T., Abbey C. K., Kim L., Damonte P., Borowsky A. D., Qi J., Tepper C. G., MacLeod C. L., Cardiff R. D., Gregg J. P., Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ Clinical Cancer Research 2006 12 8 2613 2621